Halozyme Therapeutics Inc (HALO)

[rod5247]

AG was approved as standard of care, the phase III was cut short with all patients moved to AG arm, given accelerated approval based on PFS 5 month and OS 8 month.

There is no reason for historical data to change except the subsets that did not exist before Halo's Peg and diagnostics.

The question should be, do the other companies need to start over and redo trials once Halo proves that Peg is needed to successfully treat High HA tumors or will they be allowed to continue to charge all comers for ineffective drugs that cannot reach the target.